Tempo Therapeutics utilizes proprietary Microporous Annealed Particle (MAP) technology to create fully synthetic, injectable scaffolds that modulate immune responses for tissue regeneration. This approach addresses the challenge of inflammatory and scar-forming reactions in soft tissue reconstructions, promoting the formation of vascularized tissue and improving patient outcomes.
Funding
Funding not disclosed
JJFounders
Product
Problem
Soft tissue reconstruction often faces challenges due to inflammatory responses and scar formation, leading to compromised tissue strength and function. Current implant materials can trigger a foreign body response, hindering vascularization and ultimately impacting patient outcomes.
Solution
Tempo Therapeutics develops fully synthetic, injectable scaffolds using its proprietary Microporous Annealed Particle (MAP) technology to promote regenerative immune responses for improved tissue regeneration. The MAP technology enables the creation of precision-engineered materials that modulate a patient’s immune cells, directing them to accelerate the formation of vascularized tissue volume. By evading the typical inflammatory and scar-forming foreign body response, Tempo's tissue implants enhance tissue strength and restore function. The MAP technology is also being explored for combination drug delivery, allogenic cell engraftment, and next-generation vaccine technologies.
Target Audience
The primary target audience includes biosurgery professionals focused on soft tissue reconstruction for dermal and abdominal wall indications.
Features
- Microporous Annealed Particle (MAP) technology for creating injectable porous scaffolds.
- Fully synthetic and precision-engineered materials for immunomodulation.
- Promotion of regenerative immune responses to accelerate vascularized tissue formation.
- Evasion of the foreign body response (FBR) to minimize inflammation and scarring.
- Potential applications in combination drug delivery and allogenic cell engraftment.